A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Vulnerable Patients =/> 65 Years Old With Systemic Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Dutasteride (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 18 Feb 2017 Results (n=21) presented at the 2017 Genitourinary Cancers Symposium
- 28 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.